Moreover, our study shows that detectable levels of CD137 on circulating CD8+ T cells after LN or metastatic resection in stage IIIc and IV melanoma tends to predict longer PFS for the anti-CTLA-4 + anti-PD-1 co-blockade. Here, CD8A is linked to melanoma.